FDA: Fentanyl Transdermal System Patches Recalled

Recall issued due to risk for fentanyl to be released faster than approved specification
By Beth Gilbert
HealthDay Reporter

MONDAY, Oct. 25 (HealthDay News) -- The U.S. Food and Drug Administration has notified health care professionals and patients that 18 lots of Fentanyl Transdermal System 25 mcg/hour C-II patches (Duragesic) are being voluntarily recalled. The recall was issued due to the potential for the active ingredient, fentanyl, to release faster than indicated, which can lead to adverse events among at-risk patients, including excessive sedation, respiratory depression, hypoventilation, and apnea.

The Fentanyl Transdermal System is manufactured for Actavis by Corium International in the United States and is indicated for the management of persistent, moderate to severe chronic pain that requires continuous opioid administration that cannot be treated with other methods.

Actavis identified one lot of 25 mcg/hour C-II patches that contained one patch that released the active ingredient faster than the specification approved in laboratory testing. As a precautionary measure, the company is asking all wholesalers and retailers to return the products they have in stock. The recall is not intended to impact Fentanyl Transdermal System patches sold by Actavis in Europe.

According to the FDA, "health care professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program."

More Information

Copyright © 2010 HealthDay. All rights reserved.

Powered by

jQuery UI Accordion - Default functionality

For life-long learning and continuing professional development, come to Lippincott's NursingCenter.

Nursing Jobs Plus
Featured Jobs
Recommended CE Articles Recommended Nursing Articles

What internal motivators drive RNs to pursue a BSN?
Nursing2014 , October 2014
Free access will expire on November 24, 2014.


Breast Cancer Risk Assessment in Primary Care
MCN, The American Journal of Maternal/Child Nursing, September/October 2014
Free access will expire on November 10, 2014.


Nurses spurring innovation
Nursing Management, October 2014
Free access will expire on November 10, 2014.


More Recommended Articles

Subscribe to Recommended Articles

Evidence Based Practice Skin Care Network NursingCenter Quick Links What’s Trending Events